Title:Georgetown designated R1 institution for 30th year

Earlier this year, Georgetown received the Carnegie Classification of Institutions of Higher Education’s designation as an “R1” institution—the highest classification for research and training—for the 30th year.

Georgetown invests in global, interdisciplinary research across a range of pressing issues, from advancing pancreatic cancer treatment to predicting mass migration patterns. In fiscal year 2023, the university invested more than $337 million in research and development.

Georgetown also trains the next generation of researchers in disciplines ranging from the physical and life sciences to the humanities.

Georgetown University Medical Center (GUMC) is home to the university’s most robust research enterprise, securing approximately $176 million in externally sponsored funding in fiscal year 2024 to support a broad continuum of research spanning from behavioral studies to clinical trials and population-level research.

The GUMC community is recognized internationally for its work in the areas of cancer, neuroscience, neurology, health equity, and global health. GUMC is one of few medical centers in the country to hold both a Clinical and Translational Science Award from the National Institutes of Health and a cancer center support grant from the National Cancer Institute.

Georgetown and its academic health system partner, MedStar Health, also collaborate to deliver transformative research from the laboratory to clinical care. Together, GUMC and MedStar Health earned $246 million in extramural sponsored research in fiscal year 2024.

“To ensure affordable and accessible care for all, we must find new and better ways to sustain health and respond to illness. Basic, applied, and translational research underpins the pathway to improving human health,” says Norman J. Beauchamp Jr., executive vice president for Health Sciences and executive dean for the School of Medicine.